Pliant Therapeutics shareholders elect directors, approve say-on-pay, ratify auditor at 2023 annual meeting

PLIANT THERAPEUTICS, INC.

All three Class III director nominees (Coulie, Crowell, Bruhn) elected; Coulie received 48.3M for, 1.1M withhold.
Non-binding say-on-pay proposal approved with 47.99M for, 1.38M against, 36k abstain.
Ratification of Deloitte & Touche LLP as auditor for FY2023 passed with 54.81M for, 12.5k against.
Broker non-votes totaled 5,432,103 shares on director election and say-on-pay.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

PLIANT THERAPEUTICS, INC. shareholders approved Ratification of the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-06-07 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2023-06-07

Exact text from the filing

Proposal 3: The Company’s stockholders ratified the selection of Deloitte & Touche LLP as the Company’s independent registered public accounting firm. The votes cast at the Annual Meeting were as follows: For Against Abstain 54,811,068 12,512 19,255

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

PLIANT THERAPEUTICS, INC. shareholders approved Election of Bernard Coulie, M.D., Ph.D., Gayle Crowell and Suzanne Bruhn, Ph.D. as Class III directors at the 2023-06-07 meeting.

Proposal: director election
Outcome: passed
Meeting: 2023-06-07

Exact text from the filing

Proposal 1: The Company’s stockholders approved the election of the aforementioned Class III directors recommended for election at the Annual Meeting. The Company’s stockholders voted for the Class III directors as follows: Nominee For Withhold Bernard Coulie, M.D., Ph.D. 48,316,375 1,094,357 Gayle Crowell 39,771,872 9,638,860 Suzanne Bruhn, Ph.D. 39,735,738 9,674,994 The broker non-votes for Proposal 1 totaled 5,432,103 shares of common stock.

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

PLIANT THERAPEUTICS, INC. shareholders approved Approval, by non-binding advisory vote, of the compensation of the Company’s named executive officers at the 2023-06-07 meeting.

Proposal: say on pay
Outcome: passed
Meeting: 2023-06-07

Exact text from the filing

Proposal 2: The Company’s stockholders approved, by non-binding advisory vote, the compensation of the Company’s named executive officers, as follows: For Against Abstain 47,994,590 1,379,942 36,200 The broker non-votes for Proposal 2 totaled 5,432,103 shares of common stock.

View on SEC.gov

461 shareholder votes filed in the last 30 days. Browse all shareholder votes →

PLIANT THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001746473-23-000036

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.